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IAPPPancreatic islet amyloid is a characteristic feature of type 2 diabetes. The major protein component
of islet amyloid is the polypeptide hormone known as islet amyloid polypeptide (IAPP, or amylin).
IAPP is stored with insulin in the b-cell secretory granules and is released in response to the stimuli
that lead to insulin secretion. IAPP is normally soluble and is natively unfolded in its monomeric
state, but forms islet amyloid in type 2 diabetes. Islet amyloid is not the cause of type 2 diabetes,
but it leads to b-cell dysfunction and cell death, and contributes to the failure of islet cell transplan-
tation. The mechanism of IAPP amyloid formation is not understood and the mechanisms of cyto-
toxicity are not fully deﬁned.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The deposition of amyloid in the islets of Langerhans in the pan-
creas is a characteristic pathological feature of type 2 diabetes
(T2D). Hyaline lesions in the pancreas were ﬁrst described more
than 110 years ago [1], and were later identiﬁed as amyloid. The
deposits were initially assumed to be composed of insulin or
pro-insulin or fragments of insulin, but in 1987 two groups inde-
pendently showed that the major protein component of islet amy-
loid is a 37 residue polypeptide pancreatic hormone denoted as
islet amyloid polypeptide (IAPP) or amylin [2,3]. IAPP has been
found in all mammals studied to date. The molecule is stored to-
gether with insulin in the b-cell secretory granules and is released
in response to the stimuli that lead to insulin secretion [4–6]. IAPP
is normally soluble and is natively unfolded in its monomeric state,
but forms islet amyloid in T2D [2,3,7]. IAPP can be readily induced
to form amyloid in vitro and is one of the most amyloidogenic nat-
urally occurring sequences known. Islet amyloid is not the cause of
T2D, but it does lead to b-cell dysfunction and cell death, and con-
tributes to loss of islet b-cell mass [8–10]. Rapid amyloid formationlikely contributes to the failure of islet cell transplantation and pre-
vention of amyloid formation can prolong graft survival [7,11,12].
In this review we brieﬂy discuss the processing and normal
function of IAPP, and then focus on amyloid formation by IAPP.
There are a number of critical outstanding issues in the ﬁeld. The
mechanisms of IAPP amyloid formation in vivo and in vitro are still
not understood, particularly in vivo. The site of initiation of amy-
loid formation in vivo is controversial. The nature of the toxic spe-
cies generated during IAPP amyloid formation are not well deﬁned,
nor are the mechanisms of cell death completely understood. The
mechanisms of clearance of IAPP amyloid in vivo and the role this
may play in islet amyloid formation and cytotoxicity are not fully
elucidated. Inhibitors of IAPP toxicity are less well developed than
for other amyloidogenic proteins and most studies have made use
of in vitro assays of toxicity.2. The physiological role of IAPP
2.1. IAPP is synthesized as a pre-pro hormone
IAPP is synthesized as a 89 residue pre-pro form [13]. The 22
amino acid signal peptide is cleaved to give the 67 amino acid pro-
form (proIAPP). ProIAPP is processed in the Golgi and in the insulin
secretory granule [14]. The short C- and N-terminal ﬂanking
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PC2 and PC1/3 [13]. The C-terminal cleavage leaves a Gly-Lys-Arg
tri-peptide sequence at the C-terminus. The dibasic residues at
the C-terminus are removed by carboxypeptidase E and the Gly
serves as the nitrogen donor for amidation of the C-terminus by
the peptidyl amidating mono-oxygenase complex (PAM). Amida-
tion and disulﬁde bond formation lead to mature IAPP (Fig. 1).
Incorrect processing of proIAPP has been proposed to play a role
in islet amyloid formation in vivo (see below).
IAPP is stored in the insulin secretory granule where it is local-
ized in the halo region while insulin is found in the dense core of
the granule. The concentration of IAPP in the granule is about 1–
2% that of insulin, and this is much higher than the level required
to promote rapid amyloid formation in vitro [15,16]. Thus, there
must be factors which inhibit the premature, irreversible aggrega-
tion of IAPP in the granule. The low pH environment of the granule
likely contributes since the rate of IAPP amyloid formation is
strongly pH dependent and is slower at intragranule pH [17–19].
Soluble insulin is an inhibitor of IAPP aggregation and this may
play a role in controlling intragranule aggregation, however insulin
is found in a partially crystalline state in the granule [20–24].
2.2. IAPP receptors
IAPP binds the calcitonin (CT) receptor with low afﬁnity, but the
afﬁnity is signiﬁcantly enhanced when the CT receptor forms a
complex with receptor activity-modifying proteins (RAMPs). IAPP
receptors are generated from co-expression of the CT receptor with
one of three RAMPs [25]. Interaction with RAMPs changes the spec-
iﬁcity of the CT receptor towards IAPP [26,27]. The CT receptor has
two splice variants, so there could be six different subtypes of IAPP
receptors. Despite the physiological importance of IAPP and its po-
tential clinical relevance, it is not known whether different recep-
tors are active in the peripheral tissue and CNS. It is also not known
which receptor subtype(s) binds the FDA approved analog of IAPP,
pramlintide. Thus, a more detailed understanding of IAPP receptors
is needed [28]. There are currently no approved small molecule
agonists of IAPP receptors.
2.3. IAPP has multiple physiological roles
IAPP is co-secreted with insulin from the b-cells following nutri-
ent inﬂux. The circulating concentration of IAPP is 3–5 picomolarFig. 1. Processing of human PreProIAPP to form mature IAPP. (A) The primary sequen
sequence is shown in black, the N- and C-terminal proIAPP ﬂanking regions are shown in
human proIAPP. ProIAPP is cleaved by the prohormone convertases PC(1/3) and PC2 at th
to an amidated C-terminus of IAPP. (C) The sequence of the mature 37-residue human IAP
between Cys-2 and Cys-7.in rats, rising to 15–20 picomolar upon elevation of blood glucose
[29]. The local concentration after release from the granule will be
much higher and is the more relevant number for amyloid forma-
tion. The physiological roles of soluble IAPP are not completely
understood, but IAPP is believed to play a role in controlling gastric
emptying, in maintaining glucose homeostasis, in the suppression
of glucagon release and in controlling satiety [7,30,31]. IAPP has
been proposed to play a role in regulating blood glucose levels
by inhibiting insulin secretion from the pancreas [32,33], but the
main sites of action appear to be in the CNS [34,35]. IAPP has also
been proposed to act as an adiposity signal [36]. The polypeptide
has been reported to inhibit insulin-stimulated glucose uptake
and the synthesis of glycogen in isolated rat skeletal muscle [37].
However, these effects were studied at concentrations of the poly-
peptide that are higher than physiological levels, thus the details of
IAPP’s role are still not completely clear. Several recent reviews of
the function of IAPP have recently appeared and provide a more in
depth discussion [7,29,31].
3. Residue speciﬁc effects on amyloid formation
3.1. Differences in the primary sequence of IAPP correlate with amyloid
formation in vitro and in vivo
IAPP is a member of the calcitonin related peptide family which
consists of calcitonin a- and b-calcitonin gene-related peptide
(CGRP), adrenomedullin and intermedin. The peptides share lim-
ited amino acid sequence identity, but have several important
structural features in common (Fig. 2). They all have an intramolec-
ular disulﬁde bridge near the N-terminus and an amidated
C-terminus.
IAPP is most similar to CGRP. Both are 37 residues in length,
have a conversed disulﬁde bond between residues two and seven,
contain an amidated aromatic residue at the C-terminus, and have
a tendency to form low levels of transient helical structure over
part of the sequence in their monomeric states [38–40]. Early stud-
ies showed that human IAPP (hIAPP) readily forms amyloid
in vitro, but that CGRP does not. The two peptides have reasonable
sequence similarity, with the greatest homology at the N- and C-
terminal regions, but differ most between residues 20 and 29
[41]. These observations led to the hypothesis that the sequence
within the 20–29 region determines the ability of IAPP to form
amyloid. Only humans, non-human primates, and cats form isletce of human PreProIAPP, the peptide length is 89 residues. The 22 residue signal
red, and the mature sequence in blue. (B) The primary sequence of the 67-residue
e two dibasic sites, indicated by the arrows. Additional processing by CPE/PAM leads
P. The biologically active peptide has an amidated C-terminus and a disulﬁde bridge
Fig. 2. Primary sequences of human CGRP and IAPP from different species. Residues that differ from the human IAPP sequence are highlighted in blue. The biologically active
mature sequences all have a disulﬁde bridge between Cys-2 and Cys-7 and an amidated C-terminus. Primates and cats have been reported to form islet amyloid while cows,
rodents, and dogs do not. Ferret and porcine IAPP are reported to be signiﬁcantly less amyloidogenic than human IAPP. Islet amyloid is found in the degu, but it is derived
insulin, not IAPP. Only partial sequences are available for rabbit and hare.
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with rat IAPP seemed to conﬁrm the hypothesis that IAPP amyloi-
dogenicity is controlled by the 20–29 segment. Rat IAPP and hIAPP
differ at only six positions out of 37, ﬁve of which are located be-
tween residues 20–29. The rat sequence contains three Pro resi-
dues at positions 25, 28 and 29, while the human sequence has
none. Pro is a well-known disrupter of secondary structure and is
energetically unfavorable in a b-sheet. The inability of rat IAPP to
form amyloid is attributed to the Pro substitutions [41]. These
important early studies led to the view that the amyloidogenic
properties of IAPP are dictated by the primary sequence in the
20–29 region, however the situation is more complex. Multiple
Pro substitutions outside of the 20–29 region have been shown
to abolish amyloid formation by hIAPP, as does replacement of
Asn-14 or Asn-21 [43,44]. In contrast, substitution of the rat IAPP
residues; Arg-18, Leu-23, and Val-26 by the residues found in hIA-
PP led to a weakly amyloidogenic polypeptide [45]. Thus, the 20–
29 sequence is not the only factor governing in vitro amyloid for-
mation, but there is no doubt that it is important.
The only polymorphism found in hIAPP that impacts amyloid
formation in vivo is a Ser to Gly mutation at position 20. This muta-
tion, which is found at low levels in certain Asian populations, has
been proposed to lead to a slightly higher risk of diabetes, and has
been shown to accelerate amyloid formation in vitro [7,46–49].
hIAPP contains six Asn residues and deamidation can alter the
amyloidogenic properties of proteins. Spontaneous Asn deamida-
tion is one of the most common non-enzymatic post translation
modiﬁcations and is thought to play a role in amyloid formation
by other polypeptides [50]. Deamidation proceeds via a cyclic
succinimide intermediate and, depending on how the ring is
opened, will convert an Asn residue into L or D-Asp or L or D
iso-Asp. In both cases a neutral residue is replaced by a negatively
charged residue which reduces the net charge of hIAPP, and should
thus reduce its solubility. Asn deamidation has been shown to
accelerate hIAPP amyloid formation in vitro [51] and to allow
amyloid formation by otherwise non-amyloidogenic fragments of
hIAPP [52]. Deamidation also leads to changes in the morphology
of hIAPP amyloid ﬁbrils [51].3.2. Mutational analysis of amyloid formation by IAPP
Quantitative mutational studies of amyloid formation and amy-
loid ﬁbril stability are more complicated than studies of the folding
kinetics and stability of soluble globular proteins. Mutations can
lead to the formation of different polymorphs and the determina-
tion of ﬁbril stability can be difﬁcult. There are well established
methods for determining protein stability which are ﬁrmly
grounded in theory, but this is not always the case for amyloid for-
mation. Solubility measurements can yield apparent free energies,
provided that the soluble phase is composed of monomers, and
provided that activity effects can be ignored, but it is difﬁcult to
verify these assumptions. In addition, studies which report that a
particular mutation abolishes amyloid formation may simply have
not examined the protein for a long enough time. None-the-less,
mutational analysis of amyloid formation has provided consider-
able insight and systematic studies, including proline scans, have
been reported for a number of amyloidogenic proteins. No system-
atic analysis of all of the positions of IAPP has been reported.
A number of studies have examined the consequences of muta-
tions on the amyloidogenicity of IAPP, but it is difﬁcult to compare
them since a range of conditions have been used and the rate of
IAPP aggregation can be sensitive to seemingly small changes in
buffer composition or pH. For example, some studies have used
buffers that contain 1–2% (V/V) hexaﬂuoroisoproponal (HFIP) and
even this low level of HFIP accelerates signiﬁcantly the rate of IAPP
amyloid formation. pH is also an important variable and signiﬁcant
changes in the rate of amyloid formation are observed as a function
of pH. These effects are due to changes in the protonation state of
His-18 and-or the N-terminus. Further complicating matters, the
rate of IAPP amyloid formation is strongly dependent on both the
concentration of added salt and the identity of the anion, including
common buffer components [53]. Another complication is that the
majority of studies have made use of a truncated fragment of IAPP
which lacks the ﬁrst seven residues, (IAPP8–37). These residues are
thought to be outside of the ordered amyloid core, but they could
still affect the stability of the amyloid ﬁbers by contributing to
electrostatic repulsion (see below). High throughput screens of
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fact that standard Escherichia coli based expression systems lead to
a free C-terminus instead of the physiologically relevant amidated
C-terminus. Screens which involved fusing IAPP to a reporter pro-
tein can be powerful [54], but complications might arise since the
reporter protein is much larger than IAPP.
Despite these potential complications, there is a growing body
of mutation data on hIAPP and hIAPP8–37. Table 1 summarizes
the available data from studies that have used C-terminally ami-
dated hIAPP variants and which have reported direct tests of amy-
loid formation. Many of the substitutions that impact amyloid
formation fall within the 20–29 segment reﬂecting the importance
of this region. However, mutations in the putative helical region
also alter the rate of amyloid formation, and a number of substitu-
tions within the F15, L16, and V17 segment have noticeable effects.
One model of the early stages in IAPP aggregation proposes that
interactions near residue-15 are critical and are mediated by asso-
ciation of helical conformers. This model might rationalize the sen-
sitivity of hIAPP amyloid formation to mutations at these positions
[55].
Aromatic–hydrophobic and aromatic–aromatic interactions
have been proposed to play a critical role in amyloid formation
by hIAPP. Experiments that made use of Ala scanning of short pep-
tides supported this conjecture [56], but studies that employed
more conservative aromatic to Leu substitutions revealed that aro-
matic residues are not required for amyloid formation by the full
length polypeptide [57–59]. Aromatic–aromatic interactions may
play a role in helping dictate the structure of the amyloid ﬁbril
and the kinetics of ﬁbril formation, even though they are not re-
quired for amyloid formation. Replacement of the aromatic resi-
dues has been shown to alter the rate of self-assembly of IAPP: aTable 1
(A) Mutational studies of amyloid formation by full length IAPP (A) as well as by the 8–3
Citations to the primary literature are given. ‘‘–’’no reported effect; ‘‘N’’ The mutation leads
The mutant is reported to abolish amyloid formation.
(A)triple mutant in which all three aromatic residues are replaced
by Leu formed amyloid ﬁvefold slower than wild type hIAPP [58].
In the ﬁber, the amide-containing Asn side chains are arranged
in parallel arrays along the axis of the ﬁber, and are expected to
both accept and donate hydrogen bonds to their equivalent resi-
dues in adjacent chains. A systematic examination of the role of
different Asn side chains in hIAPP structure and assembly has been
reported [44]. By replacing each Asn with the isosteric Leu, which
occupies roughly the same volume, but has no hydrogen bonding
ability, the authors found that different sites have drastically dif-
ferent consequences on amyloid kinetics. The truncated 8–37 hIA-
PP fragment was used as background in this study. Asn14Leu and
Asn21Leu mutants did not form amyloid on the experimental
timescale, and Asn14Leu could not be seeded by pre-formed wild
type ﬁbrils. Since both mutants lie in the region of predicted a-
helical propensity, the disrupted amyloid formation kinetics can
be rationalized based on different secondary structure propensities
of the two side chains. Intriguingly, Asn14 is placed into the core of
models of the amyloid ﬁbril, and its desolvation would signiﬁ-
cantly enhance the strength of the hydrogen bonds made and re-
ceived at this site, thus the Asn14Leu mutant might also impact
ﬁbril stability.
An interesting avenue for future exploration will be to use
unnatural amino acids. Much more conservative changes can be
made using non-genetically coded amino acids and, since IAPP is
normally prepared by solid phase peptide synthesis, they can be
readily incorporated. For example, analogs of aliphatic side chains
can be incorporated which preserve hydrophobicity, but signiﬁ-
cantly alter secondary structure propensities. This approach has
been proven useful in studies of protein folding transition states
and seems ripe for exploitation in studies of IAPP [60].7 fragment of IAPP (B) Residues which differ from human IAPP are indicated in red.
to faster amyloid formation; ‘‘.’’ The mutation leads to slower amyloid formation, ‘‘’’
(B)
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4.1. Monomeric IAPP does not fold to a compact structure, but it is not
a random coil
Proteins that form amyloid can be divided into two structural
classes; those which fold to a compact globular structure in their
unaggregated state and those which are natively unfolded. Impor-
tant examples of the former include b2-microglobulin and TTR,
while Ab and IAPP are important examples of the latter. Unaggre-
gated, monomeric IAPP does not fold to a globular structure, but it
is not a classic random coil. The region encompassing residues 5–
20 of hIAPP and rat IAPP has been shown via NMR to transiently
sample helical /, w angles in solution, but the level of persistent
helical structure is low [38,61].
4.2. IAPP forms helical structure on model membranes
More persistent helical structure can be induced by negatively
charged model membranes [39,62,63]. NMR studies have delin-
eated the conformation of IAPP and IAPP fragments in membrane
mimetic environments [62,63]. hIAPP adopts a helix-kink-helix
structure on model membranes with the helices located between
residues 5–17 and 20–27. Studies of peptide fragments have re-
vealed interesting differences in the structure of hIAPP and rat IAPP
in the presence of micelles. hIAPP1–19 and rat IAPP1–19 adopt verysimilar a-helical structures in the presence of detergent micelles,
but they bind to membranes in different orientations [63]. The
two peptides differ only at position 18, which is an Arg in rat IAPP
and a His in hIAPP. hIAPP1–19 inserts deeply into the hydrophobic
core of membranes, while rat IAPP1–19 binds near the surface.
The differences are believed to be dependent on the charge of res-
idue 18 and hIAPP1–19 binds near the surface, similar to rat
IAPP1–19, at acidic pH when His-18 is protonated [63,64]. Mem-
brane-bound structures of full length human and rat IAPP have also
been reported and reveal structural similarities in the N-terminal
half of the molecule, but signiﬁcant differences in the C-terminal
half. a-Helical structure is formed in the N-terminal portion of
both polypeptides [62,63,65]. The C-terminal region of rat IAPP is
almost completely disordered [62], but hIAPP has a partially helical
C-terminal region. The differences are almost certainly due to the
multiple proline residues found in rat IAPP. The role of IAPP
membrane interactions in amyloid formation and in toxicity is
discussed in subsequent sections.
5. The structure of IAPP amyloid ﬁbrils
5.1. Models of the hIAPP protoﬁbril reveal an in register, parallel
b-sheet structure
Amyloid ﬁbrils adopt a cross-b architecture in which the
b-strands run perpendicular to the ﬁbril long axis with the
Fig. 3. Structural model of the hIAPP ﬁbril derived from studies of steric zippers. (A) Ribbon diagram of the ﬁbril structure. The two stacks of symmetry related monomers are
shown. (B) Cross section of one ﬁbril layer, looking down the ﬁbril axis, showing several key residues. The aromatic residues Phe15, Phe23 and Tyr37 are shown in space ﬁlling
format along with Arg11, His18 and Ser20. The color coding corresponds to that used in panel-A. (C) Cross section of one layer showing the tight ‘‘steric zipper’’ interface
between two hIAPP monomers. Interdigitated residues Leu27, Ser29, Asn31 and Gly33 are shown in space ﬁlling representation.
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ﬁrst seven residues of hIAPP may not be part of the b-structure
core due to conformational restrictions imposed by the disulﬁde
bridge. Two atomic level models have been proposed for the hIAPP
ﬁbril and they share a number of features in common. One is
derived from solid state NMR and the other from structural studies
of hIAPP fragments. Both contain a parallel, in register arrange-
ment of the b-strands. The protoﬁbrils are made up of two columns
of symmetry related hIAPP monomers with each polypeptide
adopting a U-shaped structure. Each hIAPP monomer contains
two b-strands connected by a loop. The b-strands form intermolec-
ular hydrogen bonds with neighboring polypeptide chains within
the same column, but there are no intrachain backbone hydrogen
bonds. In the solid state NMR derived model, the ﬁrst b-strand is
made of residues 8–17 and the second encompasses residues
28–37, while the loop involves residues 18–27 [66]. Two structures
were presented which were both consistent with the experimental
NMR data. The main difference between the two had to do with the
register of side-chain orientations. In one structure, all copies of
Arg11 project into the monomer core, as do other odd-numbered
residues (Ala13, Phe15, etc.); in the other structure, Arg11, Ala13
and Phe15 are all solvent-exposed. Burial of the charged Arg side
chain is expected to be very unfavorable and thus the second
structure seems more likely.
A second model has been developed based on X-ray crystallo-
graphic studies of two penta- or hexapeptide ‘‘steric zippers’’ de-
rived from hIAPP (Fig. 3) [67]. The crystallographic and solid
state NMR derived models are similar, but differ in three features.
There are differences in the details of the atomic packing in the
core of each U-shaped monomer, differences at the bimolecular
interface between the two hIAPP monomers, and differences inthe register of side chain interdigitation at the bimolecular
interface.
Interestingly, the 20–29 segment is not part of a b-strand in
either of the models, but instead adopts a partially ordered loop
that connects the two strands. Is this compatible with the critical
role the 20–29 region plays in modulating amyloidogenicity?
Ser-28 and Ser-29 make key contacts in both models, arguing that
the Pro substitutions in rat IAPP will disrupt the interface. Multiple
Pro substitutions should also distort the bend structure due to the
steric constraints imposed by the cyclic proline side chain. Thus,
the importance of this region can be rationalized on structural
grounds, but more work is required in order to understand the
molecular basis of the signiﬁcant effect of substitutions in this re-
gion of hIAPP. Formation of the loop may also be important for ki-
netic reasons; two dimensional IR (2D IR) spectroscopy studies
have led to a model in which structure is formed early in this re-
gion [68]. Along these lines, recent work has shown that stabiliza-
tion of turn structures in the Alzheimer’s Ab peptide can enhance
signiﬁcantly the rate of amyloid formation [69].
5.2. Models of amyloid ﬁbril structure have important energetic
implications
The in-register parallel b-sheet structure of amyloid has inter-
esting implications for the energetics of amyloids. The structure
generates quasi-inﬁnite arrays of stacked identical residues. These
in-register arrangements suggest the presence of signiﬁcant ionic
interactions in amyloids. In hIAPP, both His-18 and Arg-11 are in
the structured b-sheet core or immediately adjacent to it, suggest-
ing that they could make net unfavorable contributions to the sta-
bility of the ﬁbril. Electrostatic calculations performed at the level
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Arg residues make signiﬁcant unfavorable interactions, but indi-
cate that the His residues do not do so when the His side chains
are neutral. In this case, the desolvation penalty can be overcome
by speciﬁc interactions with the imidazole ring [53]. Of course,
PB calculations may not be strictly valid for a strongly coupled sys-
tem and thus they should be taken with a grain of salt. The prob-
lem of electrostatic interactions in amyloids is somewhat
reminiscent of other systems with repetitive arrangements of like
charges such as DNA.
The N-terminus of hIAPP is expected to make unfavorable elec-
trostatic interactions in the amyloid ﬁbril, even though it may not
bewell ordered, since the Lys side chains and N-termini on adjacent
chains will be in close proximity. The importance of electrostatic
interactions in hIAPP amyloid is reﬂected in the strong salt depen-
dence of the kinetics of amyloid formation. The rate of hIAPP amy-
loid formation is signiﬁcantly accelerated with increasing salt, as
expected if charge repulsion is important. However, different salts
have different effects, indicating that salts are involved in more
than just simple electrostatic screening. A correlation with the
electroselectivity series is observed for the anions at low to moder-
ate salt concentrations, arguing that ion binding plays a role [53].6. The role of early oligomeric intermediates in IAPP amyloid
formation in vitro
6.1. The role of low order oligomers is not clear
There are conﬂicting reports on the importance of low molecu-
lar weight oligomers in IAPP amyloid formation. The nature of the
early steps of aggregation and the nature of oligomer intermedi-
ates is of much more than academic interest. Oligomers have been
proposed to be the toxic species for other amyloidogenic systems
and the lack of knowledge about the nature of the toxic species
produced during IAPP amyloid formation hinders rational drug
development [70,71]. Many studies have made use of the confor-
mation-speciﬁc polyclonal antibody A11 to detect oligomers, par-
ticularly in studies of Ab, but its speciﬁcity toward non-Ab
oligomers has been called into question, since there are reports
that it can give rise to false negatives and false positives under cer-
tain conditions [71–73].
Analytical ultracentrifugation experiments have failed to detect
low order IAPP oligomers, however those studies were performed
at low pH where IAPP aggregation is much slower and it is possible
that the mechanism of aggregation is different at neutral pH [74].
19F NMR studies of labeled IAPP also failed to detect lower order
oligomers [75]. On the other hand, chemical cross linking studies
have reported the presence of dimers, trimmers, tetramers and
higher order oligomers, while mass spectroscopy measurements
have provided evidence for dimers with a range of conformations
[76–78]. CD studies of IAPP amyloid formation also give conﬂicting
results. Some reports suggest the presence of an isodichroic point,
consistent with lack of signiﬁcantly populated intermediates,
although an isodichroic point is a necessary, but not a sufﬁcient
condition for a two state process. In contrast, other studies show
CD monitored transitions that lack an isodichroic point. It is clear
that the presence or absence of low order oligomers in IAPP amy-
loid formation is still an open question.
6.2. The kinetics of hIAPP amyloid formation is very sensitive to
conditions and sample preparation
An important practical issue that complicates studies of IAPP
oligomers and the kinetics of IAPP amyloid formation is that a wide
range of methods have been used to prepare the peptide for kineticexperiments. Many studies solubilize the peptide in ﬂuoroalcohols
or in DMSO and then dilute the resulting stock solutions into buf-
fer. Unfortunately, even 1% by volume of these co-solvents has a
signiﬁcant effect upon the kinetics of amyloid formation. Fluoroal-
cohols also stabilize helical structure in IAPP, even at these low lev-
els. Other investigations have relied upon adding buffer to dried
peptide, but the procedure used to dry IAPP can impact the results.
Some studies have prepared samples in organic solvents, typically
HFIP, and then removed the solvent, either via lyophilization or by
evaporation under nitrogen. Evaporation under a stream of nitro-
gen leads to a peptide ﬁlm and it is not clear if the peptide will
be monomeric when it is then dissolved in buffer. The presence
of already aggregated material at the start of a kinetic experiment
could signiﬁcantly impact the results. Differences in the mode of
preparation likely contribute to the wildly different lag times that
are reported in the IAPP amyloid literature. Unfortunately, some
studies do not provide detailed information about sample prepara-
tion, or about the methods used to initiate amyloid formation, and
consequently they can be difﬁcult to reproduce. One promising ap-
proach is to prepare the peptide in a ‘‘pro-form’’ that is soluble, but
which can be rapidly converted to normal IAPP. The use of so called
‘‘switch peptides’’, in which two residues are linked by an ester
bond is one manifestation of this approach [79]. The variant is sta-
ble at acidic pHs, but a rapid conversion from the ester linkage to
the more stable amide to regenerate IAPP is initiated by a simple
pH jump.
6.3. Helical intermediates may be important for IAPP amyloid
formation
hIAPP amyloid formation in vitro, in homogenous solution may
involve a helical intermediate [38,55,61,80]. Self-association and
helix formation are linked in many systems; examples include
coiled coils, other peptides with a tendency to form amphiphilic
helices and certain designed sequences. Helical wheel analysis re-
veals that hIAPP has the potential to form an amphiphilic helix be-
tween residues 5–20 [38] and NMR studies show that this region of
the chain transiently samples a-helical /, w angles. Initial aggrega-
tion might be driven by the energetic linkage between association
and helix formation. Formation of an oligomeric helical intermedi-
ate with helical structure in the N-terminal portion of hIAPP will
lead to a high local concentration of the amyloidogenic C-terminal
segment. This could lead to intermolecular b-sheet formation
which could then propagate through the sequence.
The crystal structure of a C-terminal truncated fragment of hIA-
PP fused to maltose binding protein (MBP) has been reported and
offers suggestive, albeit indirect, evidence in support of the model
[55]. Residues 8–18 and 22–27 form well ordered a-helices in the
structure with a kink separating them. The MBP-IAPP fusion forms
a dimer and the N-terminal helices from two hIAPP molecules pack
against each other with key contacts being made near Phe-15. The
consequences of replacement of Phe-15 with Ser, Ala, Asp and Lys
were examined in the truncated 8–37 fragment as part of this
work. The Ser, Ala and Asp substitutions were designed because
they were predicted to promote early dimerization of hIAPP
through the a-helical region [55]. All three substitutions acceler-
ated amyloid formation. The Phe to Lys substitution was chosen
because it was predicted to disrupt initial aggregation and it was
found to slow amyloid formation.
Studies with inhibitors appear to support the helical model. Rat
IAPP and some designed proline mutants of hIAPP are inhibitors of
hIAPP amyloid formation which is consistent with the helical inter-
mediate model [81–83]. These peptides should have a tendency to
form amphiphilic helices similar to hIAPP, since the proline substi-
tutions are not in the helical region. However, the prolines in the C-
terminal portion of these variants should inhibit formation of b-
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could function by binding to helical oligomers of hIAPP and inhib-
iting their conversion to b-structure [80,81]. The model is appeal-
ing, but it is important to remember that there is no direct
structural data on the mode of inhibition, and the inhibitors also
affect the growth phase suggesting they could have multiple ef-
fects. Insulin is a potent inhibitor of IAPP aggregation and IAPP–
insulin interactions involve contacts between the helical B-chain
of insulin and the putative helical region of hIAPP [24]. The pro-
posed mode of interaction is consistent with helical conformers
playing a role in IAPP amyloid formation. Small molecule inhibitors
of hIAPP amyloid formation that are designed to target helical
structure have also been reported [84].
6.4. Other models for early oligomers have been proposed
Ion mobility mass spectroscopy (IM-MS) in combination with
MD simulations has led to a different model of early intermediates
[76,77]. The model proposes formation of a set of conformers with
helical structure and another set which contain side by side b-hair-
pin dimers. The b-hairpin dimers are postulated to lead to amyloid
formation. The hairpin structure will require a signiﬁcant rear-
rangement of the backbone hydrogen bonding to form the stacked
column structures found in the amyloid ﬁbril models. IM-MS has
the important advantage that it can separate different conformers
in a heterogeneous mixture, but has the potential disadvantage
that one must assume that conformations detected in the gas
phase are representative of those populated by the dynamic pep-
tide in solution.
A third model has been proposed for early oligomers and is
based on studies of a non-physiological variant of hIAPP with a free
C-terminus. The free C-terminus reduces the net charge on the
peptide and could introduce new intermolecular or intramolecular
electrostatic interactions. Formation of an anti-parallel dimer was
postulated with His-18 in one chain interacting with Tyr-37 in an-
other. Interactions involving the side chain of His-18 and the C-ter-
minal Tyr were observed via NMR. These included ring stacking
interactions, but there could be a contribution from the free car-
boxylate at the C-terminus [85]. It remains to be seen if this inter-
esting structure is formed in the biologically relevant version of
hIAPP with its amidated C-terminus.
Studies that made use of Phe to Tyr FRET suggested that hIAPP
adopts conformations in the lag phase in which one of the two Phe
residues are close to the C-terminal Tyr. There is necessarily an
ambiguity in the experiments since there are two Phe residues,
F15 and F23. In apparent contrast, experiments that used the ﬂuo-
rescence analog p-cyanophenylanine (cyanoPhe) and cyanoPhe to
Tyr FRET were interpreted to show that neither residue 15 nor res-
idue 23 exhibits signiﬁcant FRET to Tyr in the lag phase, suggesting
that the positions-15 and 23 do not form close persistent contacts
with Tyr37. Thus the role of the aromatic residues in oligomer for-
mation is not completely clear [86,87].
7. In vivo amyloid deposits contain a range of components
7.1. Islet amyloid contains heparan sulfate proteoglycans and other
factors
Islet amyloid contains serum amyloid P component (SAP), apo-
lipoprotein E (apoE), and the heparan sulfate proteoglycan (HSPG)
perlecan [88,89] as well as IAPP. There is no correlation between
the presence of SAP and islet amyloid deposition. There is a corre-
lation between levels of apoE and extent of amyloid formation by
the Ab peptide in Alzheimer’s disease, but this is not the case in
T2D, and apoE knockouts do not affect islet amyloid formation[89]. However, there is growing evidence that implicates interac-
tions with the glycosaminoglycan (GAG) component of HSPGs in
IAPP amyloid formation, at least in vitro. This potentially important
factor is discussed in the next section.
7.2. Model membranes and model glucosaminoglycans accelerate IAPP
amyloid formation in vitro
hIAPP is a cationic polypeptide and has the potential to interact
with negatively charged surfaces, anionic membranes and nega-
tively charged biopolymers. Islet amyloid contains the HSPG perl-
ecan. It is not known if HSPGs are associated with amyloids
because in vivo amyloid ﬁbers are stable long lived structures that
present HSPG binding sites, or because HSPGs play a direct role in
promoting amyloid formation, but it is clear that the glycosamino-
glycan (GAG) chains of HSPGs can catalyze hIAPP amyloid forma-
tion in vitro [90]. Inhibition of GAG synthesis has been shown to
reduce hIAPP amyloid deposition in cultured islets, as does over-
expression of heparanse in a double transgenic mouse model that
over-expresses hIAPP, suggesting that interactions with HSPGs
may be important in vivo [91,92].
One model for the initiation of hIAPP amyloid formation in vivo
invokes binding of proIAPP processing intermediates to the GAG
chains of perlecan [93]. Secretion of an incompletely processed
proIAPP intermediate, (NproIAPP), that includes the N-terminal
prosequence has been reported to be increased in T2D [94,95].
The extension actually makes the polypeptide more soluble and
less amyloidogenic, but it enhances its interactions with GAGs.
Interactions with model GAGs accelerates amyloid formation by
NproIAPP in vitro and the resulting amyloid is capable of seeding
amyloid formation by fully processed hIAPP [96].
Anionic vesicles and other anionic model membranes promote
hIAPP amyloid formation in vitro and more highly charged systems
have a larger effect for high peptide to lipid ratios [97]. The mech-
anism of membrane catalyzed hIAPP aggregation is not completely
understood, but helical intermediates have been proposed to be
important [39,97–99]. Many of the studies of hIAPP–membrane
interactions have used model membranes comprised of pure anio-
nic lipids, such as phosphatidylglycerol (PG) or phosphatidylserine
(PS), or mixtures of anionic lipids with zwitterionic lipids, such as
phosphocholine (PC). The content of anionic lipid typically ranges
from 50 to 20 mol%, which is noticeably higher than found in b-
cells. b-Cells have been reported to contain between 2.5 and
13.2 mol% anionic lipids [100]. The phospholipid composition of
the b-cell is also very different from most model systems. In addi-
tion, b-cell membranes contain gangliosides and cholesterol. These
considerations naturally lead to the question of how well model
membranes mimic the in vivo environment. More complicated
model membranes made up of the phospholipids found in b-cell
membranes, but lacking cholesterol also accelerate hIAPP amyloid
formation, as do anionic model membranes that are capable of
forming lipid rafts [100–102].
8. hIAPP induced toxicity
8.1. Does islet amyloid formation have an extracellular or intracellular
origin?
The in vivo origin of islet amyloid is controversial. Early histo-
logical studies with transgenic mice are consistent with extracellu-
lar deposition and amyloid deposits observed in T2D appear to be
extracellular. However, studies that made use of rodent models in
which IAPP was over expressed indicated that islet amyloid might
have an intracellular origin [7,103,104]. Conversely, a recent study
used a cultured islet model to show that secretion of IAPP is an
Table 2
Proposed mechanisms of IAPP-induced toxicity during amyloid formation.
Mechanisms of IAPP cytotoxicity
Cell membrane disruption
Cell membrane permeabilization
Binding to FAS receptor
Endoplasmic reticulum (ER) stress
Defects in endoplasmic-reticulum-associated protein degradation (ERAD)
Unfolded protein response (UPR)
Mitochondrial dysfunction
Oxidative stress
Impairment of autophagy
Activation of inﬂammasome
Upregulation of IL-1b
Other alterations in signaling
Caspase 3 activation leading to apoptosis
Disruption of mitochondria membranes
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work used two sets of reagents: one that increased IAPP secretion,
but did not increase the amount of IAPP produced, and a second
that inhibited IAPP secretion, but maintained the level of produc-
tion. Inhibition of IAPP secretion reduced amyloid formation, while
increasing secretion increased amyloid formation and toxicity
[104]. The results are consistent with an extracellular origin of islet
amyloid, at least for the cultured islet model. The differences be-
tween the various studies might be related to the level at which
IAPP is produced and to the methods used to detect amyloid
[7,71,104]. Determining if islet amyloid has an intracellular or
extracellular origin is important since it may impact therapeutic
approaches.
8.2. Multiple mechanisms of hIAPP induced b-cell toxicity have been
proposed
The decline in b-cell function in T2D has been attributed to a
range of factors including islet inﬂammation, cholesterol accumu-
lation, glucolipotoxicity and islet amyloid formation [105–108].
Amyloid formation by hIAPP induces apoptosis and b-cell dysfunc-
tion in isolated human islets [7–9,109–112]. The pathways that
lead to hIAPP induced b-cell apoptosis are not completely charac-
terized, but progress is being made [113–115]. The cJUN N-termi-
nal kinase (JNK) pathway has been shown to mediate apoptosis in
islets and in cultured b-cells that are exposed to high concentra-
tions of hIAPP. The pathway has also been shown to do so in re-
sponse to amyloid generated from endogenous hIAPP [114].
Even a brief reading of the literature strongly implies that there
are multiple mechanisms of hIAPP induced cell death (Table 2).
Here we provide an overview; more information can be found in
the accompanying review article by Abedini and Schmidt in this is-
sue. ER stress, defects in autophagy, the enhanced production of
pro-inﬂammatory cytokines, mitochondrial membrane damage,
permeabilization of cell membranes, activation of calpain-2, recep-
tor-mediated mechanisms linked to oxidative stress and the acti-
vation of cell death signaling pathways have all been proposed to
contribute to IAPP toxicity [113–120].
ER stress has been proposed to be an important contributor to
hIAPP induced b-cell death and exogenously added hIAPP has been
reported to induce ER stress [103,121]. However, the role of ER
stress in hIAPP mediated toxicity in vivo is controversial. ER stress
is important in transgenic models that overexpress hIAPP at high
levels, but ER stress was not detected in studies of cultured islets
that produce IAPP at lower levels [122].
Defects in autophagy play a role in the toxicity of other amyloi-
dogenic proteins and overexpression of hIAPP in b-cells has been
reported to lead to impaired autophagy [116,123]. Inhibitingautophagy-lysosomal degradation enhanced hIAPP induced b-cell
apoptosis. In contrast, stimulation of autophagy protected against
IAPP toxicity [116].
hIAPP aggregates may lead to b-cell dysfunction by triggering a
localized inﬂammatory response [117,119]. Recent reports provide
evidence that hIAPP can stimulate inﬂammasome activity [117].
Inﬂammasomes are multi protein complexes that recognize a
range of pro-inﬂammatory stimuli and produce active caspase 1,
which in turn produces the active cytokines IL-1b and IL-18 by
cleaving their pro-forms. IL-1b is believed to play a part in hIA-
PP-induced b-cell dysfunction and cell death [117,119].
IAPP toxicity has also been proposed to be linked to its ability to
perturb membranes [124,125]. hIAPP amyloid ﬁbrils have been
shown to cluster on or near membranes and there is very good evi-
dence that exogenously added IAPP perturbs cell membranes
[124–126]. However, the correlation between in vitro biophysical
studies using model membranes and in vivo toxicity is less clear
and caution should be employed when extrapolating from studies
that utilize simple model membranes to the in vivo environment.
Along these lines, variants of hIAPP which do not induce b-cell
death in vivo can disrupt standard model membranes in vitro. It
is also interesting to note that exogenously added IAPP has been
reported to have very different effects on closely related cell types,
arguing that non-speciﬁc membrane disruption is not the only
mechanism of toxicity [127].
The ability of IAPP to permeabilize membranes depends on the
lipid to peptide ratio, as well as on lipid composition, pH and ionic
strength. IAPP interacts more strongly with model membranes that
contain a high fraction of anionic lipids. Most model systems con-
tain a much higher percentage of anionic lipids than found in the b-
cell membrane [100], and usually lack gangliosides and choles-
terol. This could be important since recent work has argued that
gangliosides and cholesterol mediate hIAPP membrane interac-
tions and may play a role in the uptake and clearance of hIAPP
[101,126]. More physiologically relevant model membrane sys-
tems are starting to be employed in biophysical investigations
and should provide new insights [100–102].
Mechanistic studies of IAPP induced model membrane disrup-
tion are an active area of investigation. Some studies have provided
evidence for a pore like mechanism, while others have argued in
favor of a detergent or carpeting mechanism. The process of ﬁber
growth at the membrane surface has been demonstrated to con-
tribute to membrane disruption in some cases, while other studies
have shown that formation of b-structure is not required to disrupt
membranes [125,128–133]. It is possible that multiple mecha-
nisms may be operative and their relative importance might
dependent on the speciﬁc membrane system under investigations.
More information can be found in several recent reviews [97,134].
9. Inhibition of hIAPP amyloid formation: progress is being
made, but more work is required
Inhibition of amyloid formation by hIAPP has therapeutic po-
tential. A large class of inhibitors decreases the ﬁnal amount of
amyloid ﬁbrils without affecting the length of the lag phase. If olig-
omeric species are toxic, such inhibitors may not be particularly
useful since they would only inhibit ﬁbril production instead of oli-
gomer formation. In the worst case, they could even be harmful
since they could lead to the buildup of toxic species. A more valu-
able class of inhibitors are ones that interact with the monomers or
very early oligomers and prevent them from forming toxic species.
()-Epigallocatechin 3-Gallate (EGCG), a biologically active ﬂava-
nol in green tea, is one such inhibitor. EGCG has been shown to
bind to unaggregated polypeptides and has been proposed to redi-
rect the pathway of amyloid formation to off-pathway non-toxic
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[135,136]. The compound inhibits hIAPP amyloid formation and
protects against hIAPP induced toxicity [137,138].
The mode of action of EGCG and other polyphenols with hIAPP
is not known. Interactions with aromatic residues have been pro-
posed to be critical, but this is not the case, at least for EGCG, since
the compound effectively inhibits amyloid formation by a triple
Leu mutant of hIAPP that lacks aromatic residues [138]. Schiff base
formation with protein amino groups is another potentially impor-
tant interaction, however the compound still inhibits mutants of
hIAPP which lack amino groups, likewise interactions with thiols
are not critical for EGCG’s effects on hIAPP [138]. One possibility
is that the compound interacts with the protein backbone and also
makes non-speciﬁc hydrophobic interactions with protein side-
chains. Structure function studies of the interaction of EGCG with
hIAPP have been reported [138].
Other inhibitors include sulfonated triphenyl methane deriva-
tives. These compounds are potent inhibitors of hIAPP amyloid for-
mation and of toxicity in cell culture, although they are unlikely
drug candidates [139]. A lysine-speciﬁc molecular tweezers has
been recently reported to have broad activity against a range of
amyloid forming proteins and effectively inhibits hIAPP amyloid
formation and toxicity [140]. A number of other small molecules
containing aromatic groups and polyphenols have been demon-
strated to inhibit hIAPP amyloid formation, although some of these
have to be added in signiﬁcant molar excess [78,141–146]. An
interesting class of small molecule inhibitors has also been re-
ported that targets helical intermediates [84,147]. These appear
to be the ﬁrst rationally designed small molecule inhibitors of IAPP
amyloid formation.
Several rationally designed polypeptide inhibitors have been re-
ported to inhibit hIAPP amyloid formation and toxicity. For exam-
ple, certain single proline mutations in the 20–29 region convert
hIAPP into a potent amyloid inhibitor [82,83] and a double N-
methylated variant of hIAPP has been shown to be a very effective
inhibitor of amyloid formation and hIAPP cytotoxicity [148]. As de-
scribed above, these compounds might function by targeting heli-
cal oligomers, although their mode of action is not yet deﬁned.
A range of protein based inhibitors of amyloid formation have
been described, particularly for Ab. Less work has been reported
for IAPP, although two cases have been described recently. The cal-
cium binding protein NUCB1 inhibits hIAPP amyloid formation by
‘‘capping off’’ ﬁbers and protects cells from hIAPP toxicity [149]. A
set of designed proteins have been developed that inhibit hIAPP
amyloid formation. Segments of the hIAPP sequence were grafted
into the loop region of a stable protein domain, in this case an
IgG variable heavy domain. The resulting protein inhibited amyloid
formation and protected cultured cells from hIAPP induced toxicity
[150]. One advantage of this approach is that the target epitope of
the amyloid binding domain is known, thus these molecules can be
useful reagents for probing structure.
Although progress is being made, much work still clearly needs
to be done in order to develop inhibitors of islet amyloid formation
and toxicity that will be effective in vivo. One issue that can con-
found inhibitor studies is the use of thioﬂavin-T assays to follow
amyloid formation. Many potential inhibitors can interfere with
thioﬂavin-T assays, either by simple inner ﬁlter effects, or by
quenching the ﬂuorescence of bound thioﬂavin-T, or by displacing
the bound dye. These effects can lead to false positives in inhibition
assays and it is essential to support thioﬂavin-T studies with direct
tests of amyloid formation [141,151]. There is a second potential
complication with thioﬂavin-T assays related to the behavior of
the system in the plateau region of the kinetic curve. It is possible
that molecules could remodel amyloid ﬁbrils without altering thethioﬂavin-T signal. An interesting example is provided by the
behavior of mixtures of rat and hIAPP. As noted, rat IAPP slows
amyloid formation by the human polypeptide, but the system
eventually reaches a steady state in terms of thioﬂavin-T ﬂuores-
cence and ﬁbrils can be detected by electron microscopy [81].
However, 2D IR in combination with speciﬁc isotope labeling
showed that the rat peptide actually disrupted the N-terminal
external b-sheet of the hIAPP ﬁbrils (Fig. 3). Rat IAPP then tem-
plated onto the human ﬁbrils and was induced to form b-structure
[152]. Thioﬂavin-T assays can be blind to such processes. An
important challenge in the ﬁeld is to develop non-perturbing
intrinsic probes of amyloid formation. Progress is being made with
the use of minimally perturbing unnatural ﬂuorescent amino acids
[86] and by 19F NMR [75].
10. Concluding remarks
Despite considerable progress, there are important outstanding
issues in the ﬁeld of islet amyloid; these include deﬁning the nat-
ure of the toxic species and identifying the initiation site(s) of amy-
loid formation in vivo, elucidating the mechanisms of islet amyloid
formation in vivo and in vitro, and the development of effective,
clinically relevant inhibitors. Advances in biophysical methods will
aid our understanding of the process of IAPP amyloid formation
in vitro, but a key challenge will be to connect biophysical studies
performed on simpliﬁed model systems with the situation in vivo.
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